ILARIS^®—Mechanism of Action

Targeting IL-1β, a Key Driver of Inflammation in Cryopyrin-Associated Periodic Syndromes (CAPS)

CAPS is caused by genetic mutations, often in the NLRP3 (or CIAS1) gene^1,2:

• These mutations result in overproduction of the proinflammatory cytokine, interleukin-1 beta (IL-1β)¹
• Usually autosomal-dominant inherited mutations²

Learn more about the Pathophysiology of CAPS

ILARIS® (canakinumab)—A Monoclonal Antibody That Binds to IL-1β in CAPS^1,2

• Reduces IL-1β-mediated inflammation
• Attaches itself to IL-1β for a sustained period of time
• Neutralizes IL-1β activity by blocking its interaction with IL-1 receptors
• Does not bind to IL-1α or IL-1Ra (interleukin-1 receptor antagonist)
• Normalizes serum amyloid A (SAA) and C-reactive protein (CRP) levels